Literature DB >> 21438340

[Surgical treatment for patients with pulmonary sclerosing hemangioma].

Soichi Oka1, Kenji Ono, Taiji Kuwata, Yoshika Nagata, Tetsuro Baba, Yoshiki Shigematsu, Hidehiko Shimokawa, Hidetaka Uramoto, Takeshi Hanagiri, Fumihiro Tanaka.   

Abstract

Sclerosing hemangioma of the lung, a rare disease, is a low grade malignancy possibly originating from type II pneumocytes or Clara cells. We report the clinical characteristics of 8 patients who underwent surgical resection for sclerosing hemangioma between 2005 and 2010 in our hospital. All cases were female, and the average age was 50 (range: 28-83) years old. The median tumor doubling time was 965 days, suggesting they were slowly growing tumors. In the present cases, five patients had another lung disease: lung cancer in two, metastatic lung tumor in one and atypical adenomatous hyperplasia in two patients. Intraoperative frozen section examinations were performed in seven cases. Five patients were diagnosed correctly, but two patients were diagnosed with adenocarcinoma and organizing pneumonia. As a clinical characteristics, sclerosing hemangioma in the present study showed well-demarcated and slow-growing tumor. The postoperative clinical courses of all cases were uneventful, and no findings of recurrence distant metastasis, lymph node metastasis and local recurrence after surgery were observed in any of the patients.

Entities:  

Mesh:

Year:  2011        PMID: 21438340     DOI: 10.7888/juoeh.33.41

Source DB:  PubMed          Journal:  J UOEH        ISSN: 0387-821X


  2 in total

1.  Pulmonary sclerosing pneumocytoma demonstrating intratumoral hematoma.

Authors:  Ko Lee; Mamoru Sasaki; Tomoo Kakimoto; Shojiroh Morinaga; Tatsuya Yamamoto; Arifumi Iwamaru; Kentaro Ogata; Naoto Minematsu
Journal:  Respir Med Case Rep       Date:  2019-05-29

2.  Pulmonary sclerosing hemangioma: report of two cases.

Authors:  Chuang He; Hongyang Fang; Yun Liu; Xuequan Huang; Wei Zhen; Li Ren
Journal:  World J Surg Oncol       Date:  2012-09-03       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.